The crystal structure of TREX1 explains the 3' nucleotide specificity and reveals a polyproline II helix for protein partnering - PubMed (original) (raw)
. 2007 Apr 6;282(14):10537-43.
doi: 10.1074/jbc.M700039200. Epub 2007 Feb 9.
Affiliations
- PMID: 17293595
- DOI: 10.1074/jbc.M700039200
Free article
The crystal structure of TREX1 explains the 3' nucleotide specificity and reveals a polyproline II helix for protein partnering
Udesh de Silva et al. J Biol Chem. 2007.
Free article
Abstract
The TREX1 enzyme processes DNA ends as the major 3' --> 5' exonuclease activity in human cells. Mutations in the TREX1 gene are an underlying cause of the neurological brain disease Aicardi-Goutières syndrome implicating TREX1 dysfunction in an aberrant immune response. TREX1 action during apoptosis likely prevents autoimmune reaction to DNA that would otherwise persist. To understand the impact of TREX1 mutations identified in patients with Aicardi-Goutières syndrome on structure and activity we determined the x-ray crystal structure of the dimeric mouse TREX1 protein in substrate and product complexes containing single-stranded DNA and deoxyadenosine monophosphate, respectively. The structures show the specific interactions between the bound nucleotides and the residues lining the binding pocket of the 3' terminal nucleotide within the enzyme active site that account for specificity, and provide the molecular basis for understanding mutations that lead to disease. Three mutant forms of TREX1 protein identified in patients with Aicardi-Goutières syndrome were prepared and the measured activities show that these specific mutations reduce enzyme activity by 4-35,000-fold. The structure also reveals an 8-amino acid polyproline II helix within the TREX1 enzyme that suggests a mechanism for interactions of this exonuclease with other protein complexes.
Similar articles
- The TREX1 exonuclease R114H mutation in Aicardi-Goutières syndrome and lupus reveals dimeric structure requirements for DNA degradation activity.
Orebaugh CD, Fye JM, Harvey S, Hollis T, Perrino FW. Orebaugh CD, et al. J Biol Chem. 2011 Nov 18;286(46):40246-54. doi: 10.1074/jbc.M111.297903. Epub 2011 Sep 21. J Biol Chem. 2011. PMID: 21937424 Free PMC article. - The Arg-62 residues of the TREX1 exonuclease act across the dimer interface contributing to catalysis in the opposing protomers.
Fye JM, Coffin SR, Orebaugh CD, Hollis T, Perrino FW. Fye JM, et al. J Biol Chem. 2014 Apr 18;289(16):11556-11565. doi: 10.1074/jbc.M114.559252. Epub 2014 Mar 9. J Biol Chem. 2014. PMID: 24616097 Free PMC article. - Defects in DNA degradation revealed in crystal structures of TREX1 exonuclease mutations linked to autoimmune disease.
Bailey SL, Harvey S, Perrino FW, Hollis T. Bailey SL, et al. DNA Repair (Amst). 2012 Jan 2;11(1):65-73. doi: 10.1016/j.dnarep.2011.10.007. Epub 2011 Nov 8. DNA Repair (Amst). 2012. PMID: 22071149 Free PMC article. - New roles for the major human 3'-5' exonuclease TREX1 in human disease.
Kavanagh D, Spitzer D, Kothari PH, Shaikh A, Liszewski MK, Richards A, Atkinson JP. Kavanagh D, et al. Cell Cycle. 2008 Jun 15;7(12):1718-25. doi: 10.4161/cc.7.12.6162. Epub 2008 Jun 16. Cell Cycle. 2008. PMID: 18583934 Free PMC article. Review. - TREX1 As a Potential Therapeutic Target for Autoimmune and Inflammatory Diseases.
Tao SS, Wu GC, Zhang Q, Zhang TP, Leng RX, Pan HF, Ye DQ. Tao SS, et al. Curr Pharm Des. 2019;25(30):3239-3247. doi: 10.2174/1381612825666190902113218. Curr Pharm Des. 2019. PMID: 31475890 Review.
Cited by
- TREX1 cytosolic DNA degradation correlates with autoimmune disease and cancer immunity.
Fang L, Ying S, Xu X, Wu D. Fang L, et al. Clin Exp Immunol. 2023 Mar 24;211(3):193-207. doi: 10.1093/cei/uxad017. Clin Exp Immunol. 2023. PMID: 36745566 Free PMC article. - Immune Diseases Associated with TREX1 and STING Dysfunction.
Yan N. Yan N. J Interferon Cytokine Res. 2017 May;37(5):198-206. doi: 10.1089/jir.2016.0086. J Interferon Cytokine Res. 2017. PMID: 28475463 Free PMC article. Review. - Ritonavir may inhibit exoribonuclease activity of nsp14 from the SARS-CoV-2 virus and potentiate the activity of chain terminating drugs.
Narayanan N, Nair DT. Narayanan N, et al. Int J Biol Macromol. 2021 Jan 31;168:272-278. doi: 10.1016/j.ijbiomac.2020.12.038. Epub 2020 Dec 9. Int J Biol Macromol. 2021. PMID: 33309661 Free PMC article. - The TREX1 double-stranded DNA degradation activity is defective in dominant mutations associated with autoimmune disease.
Lehtinen DA, Harvey S, Mulcahy MJ, Hollis T, Perrino FW. Lehtinen DA, et al. J Biol Chem. 2008 Nov 14;283(46):31649-56. doi: 10.1074/jbc.M806155200. Epub 2008 Sep 18. J Biol Chem. 2008. PMID: 18805785 Free PMC article. - The Role of Nucleic Acid Sensing in Controlling Microbial and Autoimmune Disorders.
Matz KM, Guzman RM, Goodman AG. Matz KM, et al. Int Rev Cell Mol Biol. 2019;345:35-136. doi: 10.1016/bs.ircmb.2018.08.002. Epub 2018 Sep 25. Int Rev Cell Mol Biol. 2019. PMID: 30904196 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases